Determining Elements of Anti-Fungal Immunity in BURN Patients

ConditionBurn
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Scientific justification Invasive fungal diseases (IFDs) pose a substantial threat, especially in immunocompromised patients, necessitating urgent research focus and therapeutic advancements. The IFI-BURN study, involving a cohort of patients with severe burn injury (n=276), revealed a significant IFD incidence of 31.6% and underscored their critical impact on morbidity and mortality. While fungi are present everywhere, for moulds within the environment and for yeasts within our microbiota, why certain patients develop IFDs and others do not, remains poorly understood. The answer most likely resides in the impact of the burn injury on the immune response, loss of skin barrier and particular predisposing immune phenotype of patients. The immune system is composed of both cellular and humoral components, but the latter is far less studied in antifungal immunity although they exert multiple antimicrobial mechanisms.

Eligibility criteria

Qualifiers

Adult patients ≥ 18 years old

Admission < 4 days following burn injury

Total burn surface Area ≥ 15%

Non opposition of the patient or his/her relatives to the research

Disqualifiers

Pregnancy

Opposition of the patient or his/her relatives

Decision not to resuscitate or to limit or stop active therapies

Trial design

Treatments tested in this trial

  • Biological sampling

Treatment groups

327 Participants
are divided into 1 treatment group